Director, Immune Phenotyping Platform

Weill Cornell Medicine; New York (NY); On-site; USD 236,000 - 287,000; Full time

Job summary

Weill Cornell Medicine seeks a Director of Immune Phenotyping Platform to lead state-of-the-art immune readout technologies, ensuring performance and scalability with instrument ownership, assay setup, standardization, and regulatory compliance.

The role collaborates with personalized TCR identification, T-cell engineering and clinical translation teams and external collaborators to deliver high-quality, reproducible immune monitoring data for translational immunology discovery and clinical

Qualifications

• Master’s Degree or Ph.D. in an appropriate field. Equivalent work experience will be considered.
• More than 10 years of related hands-on experience. Approximately 3 years or related experience in GLP/GMP or Pharmaceutical environments.
• In-depth knowledge of immune assay platforms including flow cytometry, ELISA, and cell-based functional assays.
• Familiarity with institutional and federal regulatory documentation and compliance standards.

Responsibilities

• Establish processing and storage of cell products, PBMCs, tumor biopsies, bone marrow, plasma etc samples.
• Establish multiparameter flow cytometry for absolute cell counts and phenotype; CyTOF for deep state mapping; high-purity cell sorting of immune populations including tumor-reactive T cells for single-cell -omics.
• Establish GLP-grade TCR/CAR-T study monitoring assays including bespoke product potency and phenotype analysis; bulk TCR sequencing; VCN analysis (ddPCR); Integration site analysis; plasma cytokines/chemokine assay; plasma inflammatory proteomics; ctDNA.
• Establish multiparameter microscopy and segmentation-enriched WES/RNAseq immunogenetics analytics to evaluate target antigen expression heterogeneity and tumor genetic alterations mediating immune escape.
• Establish methods for assessing tumor antigen specificity of T clonotypes including scRNA/TCRseq; and functional HTS methods including massive parallel testing of functional reactivity to autologous tumor, organoids, cell lines, APCs, peptides.
• Establish a platform for massively parallel TCR cloning and pooled functional screening in reporter and primary T cells for HTS; develop downstream HTS assays of specificity and function including CTL assays.
• Establish assays for validation of TCR specificity, avidity (Kd, Koff, Kon), function, high-throughput peptide dilution arrays.
• Establish a state-of-the-art platform for evaluation of alloreactivity and unintended HLA interactions, off-target risk assessment including X-scan, random peptide libraries, library-on-library for HTS; APC lines and normal tissue in vitro surrogates.
• Establish methods for microscopy-based HTS and deeper cell characterization using time lapse cell imaging; imaging flow cytometry, confocal microscopy, high content imaging, cryo-expansion microcopy.
• Establish tissue-based immune interrogation assays including spatial -omics coupled with TCR RNAscope and capture of transferred engineered T cells.

Skills

Flow cytometry

ELISA

Single-cell sequencing

TCR/CAR-T

Education

Master’s degree

PhD

Tools

CyTOF

ddPCR

WES

RNAseq

Job description

Weill Cornell Medicine seeks a Director of Immune Phenotyping Platform to lead state-of-the-art immune readout technologies, ensuring performance and scalability with instrument ownership, assay setup, standardization, and regulatory compliance.

The role collaborates with personalized TCR identification, T-cell engineering and clinical translation teams and external collaborators to deliver high-quality, reproducible immune monitoring data for translational immunology discovery and clinical